Designing Multi-Target Drugs

個数：

Designing Multi-Target Drugs

Morphy, J. Richard (EDT)/ Harris, C John (EDT)

ウェブストア価格 ¥45,010（本体¥40,919）
Royal Society of Chemistry（2012/04発売）
外貨定価 US$ 216.00
ポイント 409pt

提携先の海外書籍取次会社に在庫がございます。通常3週間で発送いたします。
【重要ご説明事項】
1. 納期遅延や、ご入手不能となる場合が若干ございます。
2. 複数冊ご注文の場合は、ご注文数量が揃ってからまとめて発送いたします。
3. 美品のご指定は承りかねます。

●3Dセキュア導入とクレジットカードによるお支払いについて

【入荷遅延について】
世界情勢の影響により、海外からお取り寄せとなる洋書・洋古書の入荷が、表示している標準的な納期よりも遅延する場合がございます。
おそれいりますが、あらかじめご了承くださいますようお願い申し上げます。

◆画像の表紙や帯等は実物とは異なる場合があります。

◆ウェブストアでの洋書販売価格は、弊社店舗等での販売価格とは異なります。
また、洋書販売価格は、ご注文確定時点での日本円価格となります。
ご注文確定後に、同じ洋書の販売価格が変動しても、それは反映されません。

製本 Hardcover:ハードカバー版／ページ数 394 p.
言語 ENG
商品コード 9781849733625
DDC分類 615.19

Full Description

Multi-target drug discovery (MTDD) is an emerging area of increasing interest to the drug discovery community. Drugs that modulate several targets have the potential for an improved balance of efficacy and safety compared to single targets agents. Although there are a number of marketed drugs that are thought to derive their therapeutic benefit by virtue of interacting with multiple targets, the majority of these were discovered accidentally. Written by world renowned experts, this is the first book to gather together knowledge and experiences of the rational discovery of multi-target drugs. It describes the current state of the art, the achievements and the challenges of the field and importantly the lessons learned by researchers to date and their application to future MTDD.

Preface;

Forewords;

Simple drugs do not cure complex diseases - the need for multi-targeted drugs;

Clinical Need and Rationale for Multi-Target Drugs in Psychiatry;

Drug molecules and biology: network and systems aspects;

Chemoinformatic approaches to target identification;

In vitro Panel Screening - Biological Fingerprinting;

Phenotypic and in vivo Screening;

Lead Discovery and Drug Repurposing;

Target/s identification approaches - experimental biological approaches;

Historical strategies for lead generation;

In silico Lead Generation Approaches in Multi-Target Drug Discovery;

The challenges of multi-target lead optimization;

Combination agents versus multi-targeted agents - pros and cons;

CASE STUDIES: The Discovery of Lapatinib;

Identification and optimization of dual PI3K/mTOR inhibitors;

Discovery of HDAC-inhibiting multi-target inhibitors;

Targeting protein-protein interactions;

dual inhibitors of Bcl-2 and Bcl-xL;

Discovery of the anti-psychotic drug, Ziprasidone;

The Rational Design of Triple Reuptake Inhibitors for the Treatment of Depression;

Discovery of multi-target agents for neurological diseases via ligand design;

Designing Drugs with Dual Activity: Novel Dual Angiotensin II and Endothelin Receptor Antagonists;

Case study 10: Ethyl Urea Inhibitors of the Bacterial Type II Topoisomerases DNA Gyrase (GyrB) and Topoisomerase IV (ParE);

Epilogue;

Index